The following is a description of some corporate transactions in which Bill Fabbri has represented clients:
Business Development Transactions
Represented biopharma company in $250 million license and collaboration agreement with another biopharma company
Represented biopharma company in amendment of $65 million license and research agreement, including return of rights to certain compounds and increase in royalty and milestone payments
Represented biopharma company in $29 million drug development joint venture with mid-sized pharmaceutical company, including licensing, financing and operating agreements
Represented biopharma company in $24 million multi-party consortium funded by Gates Foundation
Represented CRO in amendment to Clinical Development Agreement with pharmaceutical company to provide for tiered-royalty and $10 million in success-based milestones
Represented biopharma company in termination of drug development joint venture and reacquisition of full development, manufacturing and commercialization rights
Represented specialized clinical development company in multi-Phase clinical development agreement with biopharma company containing cash, restricted stock and royalty-based consideration.
Represented biopharma company in collaboration, supply and distribution agreement with South American distributor
Represented biopharma company in in-license of oral drug delivery technology from mid-sized pharma company for development of oral version of lead drug candidate
Represented biopharma company in $5 million exclusive license agreement for patent portfolio resolving potential interference and inventorship issues
Represented biopharma company in return of compound class under a research and license agreement
Represented biopharma company in freedom-to-operate license
Private Offerings
Represented biopharma company in $20 million equity line of credit
Represented biopharma company in 7 PIPEs of preferred stock and warrants and common stock and warrants raising a total of $50 million
Represented limited partnership in investment of up to $7 million of Series A preferred stock in medical device/diagnostic company
Represented drug delivery company in a private sale of $2 million of common stock
Represented VC in $13 million first round financing of telecom software start-up
Represented private QoS software developer in $25 million Series E Preferred Stock financing
Represented borrower in $7 million revolving credit facility with Fleet Bank
Public Offerings
Represented Issuers and Underwriters in aggregate of $575 million of public offerings of common stock, preferred stock and debt
Providing Corporate Legal Services to the Life Science Community
